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Introduction
Bone development requires a complex remodeling of the
extracellular matrix, and this is in large part mediated by matrix
metalloproteinases (MMPs). Osteoblastic cells express several
MMPs implicated in bone morphogenesis (Ortega et al., 2003),
osteoblast and chondrocyte migration (Blavier and Delaisse,
1995; Onodera et al., 2004), unmineralized matrix degradation
(Uchida et al., 2001), and cell invasion (Javed et al., 2005).
Evidence from gene-knockout studies shows that bone
formation and resorption are regulated by nitric oxide (NO):
mice deficient in endothelial NO synthase (eNOS) or cyclic
guanosine 3,5-monophosphate (cGMP)-dependent protein
kinase (PKG) show bone abnormalities (Aguirre et al., 2001;
Chae et al., 1997; Chikuda et al., 2004; Miyazawa et al., 2002;
Otsuka et al., 1998; Talts et al., 1998) and inducible NO
synthase (iNOS)-null mice show imbalances in bone
osteogenenis (van’t Hof et al., 2000). However, the
mechanisms through which NO influences osteogenesis remain
unclear.
The transcription factor core binding factor 1 (Cbfa-1; also
called AML-3, Runx-2 and PEBP.2) is a key mediator of bone
differentiation. Cbfa-1 is required for osteoblastic cell
differentiation and ossification (Franceschi and Xiao, 2003;
Lian et al., 2004), and its expression correlates with the
transition of osteoblasts from the proliferative to the
differentiated phenotype (Pratap et al., 2003). Cbfa-1 is closely
associated with osteogenic processes known to involve MMPs
and NO. Cbfa-1 mediates NO-induced expression of genistein
in murine bone marrow stromal cells (BMSCs) (Pan et al.,
2005) and of osteoprotegerin in ovarectomized rats (Wang et
al., 2004b) and the gene encoding MMP-13 is one of many
regulated by Cbfa-1 in osteoblasts (Hess et al., 2001; Jimenez
et al., 1999; Porte et al., 1999; Selvamurugan et al., 2000;
Winchester et al., 2000).
It was already known that NO is involved in bone
metabolism, that Cbfa-1 is implicated in mediating MMP
expression, and that NO regulates the expression and activity
of MMP-13 in endothelium (Lopez-Rivera et al., 2005); this
led us to investigate the mechanisms responsible for such
actions. Here, we investigated the action of NO during
differentiation of the osteoblastic cell line MC3T3-E1. NO
induces MMP-13 expression and activity, a process in which
Cbfa-1 is required. Our findings further indicate that NO might
phosphorylate Cbfa-1 by PKG, thereby suggesting a molecular
mechanism through which NO regulates bone metabolism.
Results
MC3T3-E1 differentiation induces iNOS and MMP-13
expression, and NO regulates MMP-13 production
To test the expression of MMP-13 and iNOS in response to cell
differentiation, we incubated MC3T3-E1 cells in the presence
of 50 M ascorbic acid and 10 mM -glycerol phosphate, to
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requires remodeling of the extracellular matrix. Although
underlying mechanisms have not been elucidated, evidence
points to the participation of the nitric oxide (NO) and
cyclic guanosine 3,5-monophosphate (cGMP) system.
Here, we detected increased matrix metalloproteinase
(MMP)-13 mRNA, protein and activity, as well as increased
inducible NO synthase (iNOS) and NO production during
the differentiation of MC3T3-E1 osteoblasts.
Transcriptional activity of the MMP-13 promoter was
augmented by NO, 8-bromo-cGMP (8-Br-cGMP), and by
a dominant-positive form of protein kinase G (PKG1-).
The stimulatory effect on the MMP-13 promoter was
partially inhibited by mutation of the osteoblast-specific
element 2 (OSE-2) binding site. Core binding factor-1
(Cbfa-1) expression peaked at 7 days of differentiation, and
was phosphorylated by PKG in vitro. Cbfa-1 was localized
to cell nuclei, and its translocation was inhibited by the
iNOS inhibitor 1400W. Immunohistological examination
revealed that MMP-13 and Cbfa-1 expression levels are
both reduced in 17-day-old embryos of iNOS-deficient
mice. Silencing of Cbfa-1 mRNA blocked MMP-13
expression without interfering with endogenous NO
production, confirming its role in NO-induced MMP-13
expression by MC3T3-E1 cells. The results described here
suggest a mechanism by which NO regulates osteogenesis.
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induce osteoblast differentiation as reported (Fratzl-Zelman et
al., 1998). After 14 and 21 days of incubation, we found a
significant increase of MMP-13 protein and iNOS protein as
detected by immunoblot, as well as NO production from
culture supernatants collected at the time points indicated
(Fig. 1).
MMP-13 has been previously reported by others to be
induced by ascorbate-mediated differentiation of MC3T3-E1
cells (Mizutani et al., 2001). However, the contribution of NO
on such effect is unknown. By incubating differentiated
MC3T3-E1 cells with the pharmacological inhibitor of iNOS
1400W (200 M), we found a decrease in MMP-13 levels (Fig.
2A), gelatinolytic activity (Fig. 2B) and MMP-13-associated
activity (Fig. 2C), whereas MT1-MMP (a MMP expressed in
MC3T3-E1 cells) did not show variation in response to 1400W
(Fig. 2A, lower panel).
iNOS transcriptionally regulates MMP-13 expression in
MC3T3-E1 cells
To analyze the effect of NO in the transcriptional regulation of
MMP-13, we transiently transfected MC3T3-E1 with pMMP-
13 WT, a plasmid containing the MMP-13 promoter region
fused to a luciferase reporter gene. Administration of
diethylamine NONOate (DEA-NO) (100 M) induced the
activity of MMP-13 promoter significantly above control cells,
whereas incubation with 1400W alone (200 M) brought
MMP-13 promoter activity below basal levels (Fig. 3A).
We investigated the relevance of the NO-cGMP-PKG
pathway in NO-mediated MMP-13 expression, and found that
DEA-NO (100 M) and the cGMP-soluble analog 8-Br-cGMP
(10 M) stimulated MMP-13 promoter activity. Furthermore,
in cells challenged with the pharmacological inhibitor of
soluble guanylate cyclase (sGC) [1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ) (20 M), the stimulatory effect of
NO was partially suppressed (Fig. 3B). In addition,
overexpression of the PKG1- dominant-positive isoform
(Zaragoza et al., 2002b) also stimulated MMP-13 promoter
activity and MMP-13 expression (Fig. 3C).
To test the relevance of Cbfa-1 in MMP-13 expression
mediated by the NO-cGMP pathway, MC3T3-E1 cells were
transiently transfected with pMMP-13 WT or pMMP-13
OSE2, a plasmid encoding a mutation at the OSE-2 binding
site of Cbfa-1. In cells transfected with pMMP-13 OSE2, the
stimulatory effects of DEA-NO and 8-Br-cGMP were
significantly reduced, as compared with cells transfected with
pMMP-13 WT (Fig. 4A and 4B respectively), suggesting that
the NO-cGMP pathway regulates the expression of MMP-13
in MC3T3-E1 by the targeted activation of Cbfa-1.
Nuclear localization of Cbfa-1 during MC3T3-E1
differentiation is prevented by inhibition of iNOS, and
Cbfa-1 is phosphorylated by PKG in vitro
Cbfa-1 protein expression was markedly increased at day 7 of
MC3T3-E1 differentiation (Fig. 5A). Participation of the NO-
cGMP pathway seems unlikely since Cbfa-1 levels remained
Fig. 1. MMP13 and iNOS protein levels during MC3T3-E1
differentiation. MC3T3-E1 cells were analyzed at the time points
indicated in the presence of 50 g/ml ascorbic acid and 10 mM -
glycerol phosphate. MMP-13 (upper panel) and iNOS (lower panel)
were detected by immunoblot (n=3), whereas NO production was
detected by Griess reaction (lower graph) (n=3).
Fig. 2. NO reduces MMP-13 protein and MMP-13 activity during
MC3T3-E1 differentiation. MC3T3-E1 cells were induced to
differentiate with ascorbic acid (AA) and -glycerol phosphate
(GP), and analyzed at the time points indicated in the presence or
absence of 200 M 1400W. (A) Immunoblot of MMP-13 and MT1-
MMP (n=3). (B) Gelatin zimography (n=3). (C) Detection of MMP-
13 activity by using a fluorogenic substrate from culture supernatants












unchanged in the presence of either NO or 8Br-cGMP (Fig.
5B). Taking into account this result, we evaluated alternative
effects of NO, which could explain the effect on Cbfa-1-
mediated transcriptional activity of MMP-13. We first
monitored the pattern of Cbfa-1 expression by confocal
microscopy. Cell differentiation induced Cbfa-1 expression
and nuclear localization by day 7 (Fig. 5C, panels i versus
panels ii), whereas, strikingly, inhibition of iNOS with 1400W
(200 M) markedly reduced nuclear localization of Cbfa-1
(Fig. 5C, day 7, panels iii versus panels ii), and the result was
further confirmed by immunoblot of nuclear and cytosolic
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extracts from MC3T3-E1 cells at days 7 and 14 of
differentiation (Fig. 5D). Taken together, these results suggest
nuclear localization of Cbfa-1 as a mechanism elicited by NO
during MMP-13 expression in MC3T3-E1 cells.
The fact that the NO-cGMP-PKG signaling pathway
regulates Cbfa-1-mediated MMP-13 transcription, and taking
into account that iNOS inhibition reduces nuclear levels of
Cbfa-1, lead us to investigate if NO might regulate nuclear
Cbfa-1 levels by PKG-mediated phosphorylation. During in
vitro kinase assays, we found that recombinant purified Cbfa-
1 was phosphorylated by recombinant PKG exclusively in the
presence of cGMP (Fig. 5E, lane 4 versus lane 5).
Autophosphorylation of PKG was also detected as reported by
others (Chu et al., 1998; Smith et al., 2000). Thus, the NO-
cGMP-PKG pathway might drive Cbfa-1-dependent gene
expression in osteoblasts by regulating nuclear translocation of
Cbfa-1.
Cbfa-1 expression is reduced in the embryos of iNOS-
null mice
To analyze the influence of NO on Cbfa-1 localization in vivo,
we detected the expression of Cbfa-1 and MMP-13 over a time
Fig. 3. The NO-cGMP-PKG pathway transcriptionally regulates
MMP-13 expression during MC3T3-E1 differentiation. MC3T3-E1
cells were induced to differentiate and analyzed at the time points
indicated. (A) MMP-13 promoter activity in MC3T3-E1 transiently
transfected with pMMP-13 WT, and incubated with 100 M DEA-
NO, or 200 M of the iNOS inhibitor 1400W (n=3, mean ± s.d.,
*P<0.05 versus control). (B) Measurement of MMP-13 promoter
activity in MC3T3-E1 cells transiently transfected with pMMP-13
WT, and incubated with 100 M DEA-NO, 10 M 8-Br-cGMP, 20
M ODQ, and 100 M DEA-NO plus 20 M ODQ (n=3, mean ±
s.d., *P<0.05 versus control, #P<0.05 versus DEA-NO).
(C) Measurement of MMP-13 promoter activity in MC3T3-E1 cells
transiently transfected with pMMP-13 WT and co-transfected with a
dominant-positive construct of PKG1- (black bars) (n=3, mean ±
s.d., *P<0.05 versus control). MMP-13 mRNA was evaluated in
these cells by RT-PCR analysis using GAPDH as a control (inset
shows a representative experiment and a densitometric analysis of
three independent experiments, mean ± s.d., *P<0.05 versus absence
of PKG).
Fig. 4. The NO-cGMP-PKG pathway regulates MMP-13 expression
through the Cbfa-1 responsive element OSE-2. Measurement of
MMP-13 promoter activity in MC3T3-E1 cells transiently
transfected with pMMP-13 WT or pMMP-13 OSE-2. (A) In the
absence or presence of 8-Br-cGMP (8BrcGMP). (B) In the absence
or presence or DEA-NO (n=3, mean ± s.d., *P<0.05 versus non-
treated with 8-Br-cGMP or DEA-NO, #P<0.05 pMMP-13 OSE-2
versus pMMP-13 WT non-stimulated with 8-Br-cGMP or DEA-NO,
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course of embryonic development in wild-type (WT) and
iNOS-null mice (Fig. 6, mouse embryos at 17 days post-
coitum). Cbfa-1 and MMP-13 levels were mostly detected in
bone structures and, to a lesser extent, in surrounding tissues.
However, in iNOS-null mice, the overall staining for Cbfa-1
and MMP-13 was significantly reduced (Fig. 6; Cbfa-1, A
versus C; MMP-13, B versus D). A more detailed analysis
shows a clear reduction in iNOS-null embryos of MMP-13 and
Cbfa-1 in the ribs (Fig. 6; MMP-13, J versus L; Cbfa-1, I versus
K) and vertebrae (Fig. 6; MMP-13, N versus P; Cbfa-1, M
versus O). A similar pattern could also be detected in
craniofacial structures. The Meckel’s cartilage was negative for
MMP-13 and Cbfa-1 in iNOS WT and iNOS-null embryos, as
well as chondrogenic regions of vertebrae. However, MMP-13
and Cbfa-1 levels were reduced in the nasal bones, frontal
bones and mandibles of iNOS-null embryos (Fig. 6; MMP-13,
F versus H; Cbfa-1, E versus G), pointing towards the relevance
of iNOS during mouse development. This result was further
verified by immunoblot of lysates from 17-day-old WT and
iNOS-deficient embryos (Fig. 6Q).
NO-cGMP-mediated expression of MMP-13 depends
on Cbfa-1
To determine the contribution of Cbfa-1 to NO-mediated
MMP-13 expression, we silenced the expression of Cbfa-1
by RNA interference. In cells in which Cbfa-1 was silenced,
MMP-13 protein abundance was three times lower than in
non-silenced cells (Fig. 7, upper left), even when NO levels
increased as a result of cell differentiation (Fig. 7, lower
graph). By contrast, gene silencing of GAPDH did not affect
either MMP-13 or Cbfa-1 expression levels (Fig. 7, upper
right). This result suggests that, even when NO levels are
kept high, the presence of Cbfa-1 is essential for MMP-13
expression. This is consistent with the concept of Cbfa-1 as
a target for NO-cGMP-PKG in the expression of MMP-13
in this osteoblastic cell line.
Discussion
Our results indicate that NO is an important mediator in the
expression of MMP-13 during osteoblast differentiation,
providing insights into the molecular signaling pathways
activated by NO.
The active involvement of NO in bone healing (Corbett et
al., 1999; Diwan et al., 2000; Wang et al., 2004a; Zhu et al.,
2001), bone development (Aguirre et al., 2001; Armour et
al., 2001; Collin-Osdoby et al., 1995; Turner et al., 1997;
van’t Hof and Ralston, 2001) and bone loss (Cuzzocrea et
al., 2003; Wang et al., 2004b) has been reported. Mice
lacking eNOS present profound abnormalities in bone
formation, and osteoblasts from calvarial explants show
retarded proliferation and differentiation. However, the
molecular target(s) of NO are not well understood. MMPs,
and in particular MMP-13, can be considered good
candidates for the actions of NO, owing to their crucial
involvement in bone healing (Henle et al., 2005; Yamagiwa
et al., 1999; Yang et al., 2004), bone development (Inada et
al., 2004; Stickens et al., 2004) and bone loss (Pelletier et
al., 2004). Previous work has shown that the transcription
factor Cbfa-1, which is fundamental to osteoblast
differentiation and regulates the expression of different
MMPs, is significantly reduced in osteoblasts from neonatal
eNOS-null mice (Afzal et al., 2004). Even when MMP-13
induction in differentiating osteoblasts has been documented
(Mizutani et al., 2001), the relationship between NO and
MMP-13 expression in bone cells has not been investigated.
We found that osteoblast differentiation induced iNOS
expression, and that iNOS regulates MMP-13 protein in
MC3T3-E1 cells at the transcriptional level through the
cGMP pathway, through the activation of the transcription
factor Cbfa-1.
The increase of iNOS expression led us to investigate the
Fig. 5. Effect of the NO-cGMP-PKG pathway on Cbfa-1 regulation in
MC3T3-E1 cells. (A) Immunoblot analysis of Cbfa-1 over a time
course of MC3T3-E1 differentiation (n=3). (B) Immunoblot analysis of
Cbfa-1 over a time course of MC3T3-E1 differentiation in the presence
of DEA-NO or 8Br-cGMP (n=3). (C) Immunocytochemistry analysis
of Cbfa-1 (red) at day 7 of MC3T3-E1 differentiation. Cells were
induced to differentiate (ii), or not (i), or induced to differentiate in the
presence of 200 M 1400W (iii). Nuclei were visualized with Hoechst
(blue) (n=3). Bars, 25 m. (D) Cbfa-1 expression from nuclear extracts
and cytosolic extracts of MC3T3-E1 after 7 and 14 days of
differentiation. PARP was detected as a control for nuclear integrity
(n=3). (E) Recombinant Cbfa-1 (2 g) was incubated with 100 units of
PKG or 100 units of denatured PKG (bPKG) in phosphorylation buffer
(see Materials and Methods), containing 1 Ci of [32P]-ATP, in the
presence or absence of 100 M cGMP. Samples were electrophoresed












effect on MMP-13 in vivo. The analysis of Cbfa-1 and MMP-
13 in WT and iNOS-deficient mouse embryos revealed a
marked reduction in the expression of both proteins in the
absence of NO. Taken together, these results point towards
MMP-13 as a target for the role of NO in bone development,
and Cbfa-1 as a mediator of its action.
MMP-13 and Cbfa-1 have important roles in bone formation
(Stahle-Backdahl et al., 1997). The mechanism leading to
increased MMP-13 expression in osteoblasts depends on Cbfa-
1 activation (Hess et al., 2001; Jimenez et al., 1999; Porte et al.,
Journal of Cell Science 119 (9)
1999; Selvamurugan et al., 2000; Winchester et al., 2000). By
inhibiting the expression of Cbfa-1 in RNA interference assays,
we found that Cbfa-1 regulates NO-mediated MMP-13
expression in MC3T3-E1 cells. Cbfa-1 expression peaked after
7 days of MC3T3-E1 differentiation [as shown by others
(Perinpanayagam et al., 2004)], whereas MMP-13 was maximal
after 14 days. Cbfa-1 expression is not regulated by NO.
However, the presence of Cbfa-1 in the nucleus was still evident
at day 14 of differentiation (Fig. 5D), and the process appears
to be dependent on NO, thus accounting for the effect on MMP-
13 expression. In addition, Cbfa-1 enables cells to
evade proliferation (Pratap et al., 2003) and Cbfa-1
expression has been reported to be negatively
regulated by Cbfa-1 itself in cultured cells, which
could provide a negative-feedback loop that might be
used as a repression mechanism (Tou et al., 2003).
Involvement of the NO-cGMP in the activation of
Cbfa-1-mediated gene expression has been reported
in the case of genistein (Pan et al., 2005). The results
shown here, as well as in endothelial cells (Zaragoza
et al., 2002a; Zaragoza et al., 2002b), identify cGMP
as a mediator of NO-induced expression of MMP-
13. In this setting, phosphorylation of Cbfa-1 by
PKG might have an important role. Cbfa-1 activity
is inhibited by protein kinase inhibitors. In
particular, NO increases osteoprotegerin expression
through the activation of Cbfa-1 in ovariectomized
rats, and the effect is inhibited with herbimycin A
(Wang et al., 2004b), a tyrosine kinase inhibitor.
Cbfa-1 might become phosphorylated by the
mitogen-activated protein kinase (MAPK)-
extracellular signal-regulated protein kinase (ERK)
pathway, and by protein kinase A (PKA) under
certain conditions (Franceschi et al., 2003).
However, the kinase(s) responsible for NO-mediated
Cbfa-1 activation have not been identified yet. In
endothelial cells, MMP-13 expression is regulated
by NO through the cGMP-PKG and ERK pathways
(Zaragoza et al., 2002b). Taking into account the
data shown by others (Franceschi et al., 2003; Pan
et al., 2005), and the fact that overexpression of PKG
stimulates both the activity of the MMP-13 promoter
and MMP-13 expression, we infer that, in
osteoblasts, PKG is also able to phosphorylate Cbfa-
1. Our in vitro phosphorylation assays confirm that
recombinant PKG phosphorylates Cbfa-1 in a
cGMP-dependent manner. In silico analysis reveals
three putative consensus sequences of Cbfa-1
susceptible to PKG phosphorylation (Thr89,
Thr104, Ser340).
Our data provide a link between NO and Cbfa-1,
which converge on the expression of MMP-13, and
which might have consequences for bone
osteogenesis. Future work should contribute to
deciphering the pathophysiological relevance of this
pathway in animal and human models of disease.
Materials and Methods
Mice and cells
Wild-type C57BL/6 mice and mice disrupted for the gene encoding
iNOS were housed in our animal facilities in isolated rooms. Mouse
Fig. 6. Cbfa-1 and MMP-13 expression are reduced in iNOS-deficient embryos.
Immunohistological detection of Cbfa-1 (A,C,E,G,I,K,M,O) and MMP-13
(B,D,F,H,J,L,N,P) on sections from iNOS wild-type (WT) (left side) and iNOS-
deficient (right side) 17-day-old embryos. Experiments were performed in
triplicate on sections from three different embryos. Skulls (E,F,GH), ribs
(I,J,K,L) and vertebrae (M,N,O,P) are magnified. m, Meckel’s cartilage; mb,
maxillary bone; nb, nasal bone; hbc, cartilage of the hyoid bone; cc, cricoid
cartilage. (Q) Immunoblot detecting the levels of Cbfa-1, MMP-13 and GAPDH
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embryos were isolated at regular intervals, embedded in paraffin and sections were
obtained for immunohistochemistry.
The osteoblastic cell line MC3T3-E1 was kindly donated by M. Ángel Peñalva
(CIB, CSIC, Madrid, Spain). MC3T3-E1 monolayers were grown in 6-well plates,
and fed with alpha-minimal essential medium (-MEM), supplemented with 10%
FBS and antibiotics. To differentiate MC3T3-E1, cells were cultured for 21 days in
the presence of ascorbic acid (50 g/ml) and -glycerol phosphate (10 mM).
Reagents
Cell culture supplies were from Falcon (Beckton-Dickson), serum was from
BioWhittaker, antibiotics were from Sigma, RT-PCR reagents were from GIBCO
and Taq DNA polymerase was from Applied Biosystems. The Dual Luciferase
Reporter System, RNAase inhibitor RNasin, pGL3 plasmids and restriction
endonucleases were from Promega. Autoradiography film was from Kodak.
Polyvinylidene fluoride (PVDF) protein transfer membranes were from Millipore,
and the electrochemiluminescence (ECL)-detecting immunoblot system was from
GE. Optimem and Lipofectamine were from GIBCO-BRL. EDTA-free protease
inhibitor cocktail tablets were from Roche. Polyclonal antibodies to MMP-13, and
active bovine protein kinase G, isoform 1 (form Spodoptera frugiperda) were from
Calbiochem. Anti-Cbfa-1 monoclonal and anti-iNOS polyclonal antibodies were
form SantaCruz Biotechnologies. Anti-MT1-MMP antibody was kindly donated by
A. García-Arroyo (CNIC, Madrid, Spain). The Silencer siRNA Construction Kit
was from Ambion.
Plasmids
Plasmid pMMP-13 WT contains a functional part of the 5 promoter of the human
MMP-13 (GenBank accession no: NM_002427) located upstream of a luciferase
reporter gene. Plasmid pMMP-13 OSE-2 is identical to pMMP-13 WT except for
a mutation at the OSE-2 responsive element (Pendas et al., 1997). Dominant-
positive PKG, containing the catalytic subunit of cGMP-dependent protein kinase,
was expressed in MC3T3-E1 cells as described (Zaragoza et al., 2002b).
Recombinant Cbfa-1 was cloned by inserting Cbfa-1 cDNA into the SphI and SalI
restriction sites of the pQ30 vector (Qiagen).
Nitrite assay
Nitrite concentration in culture supernatants was determined by a modification of
the Griess assay as described (Zaragoza et al., 2002b).
Immunoblot analysis
Cell lysate extraction and protein immunoblots were performed as described
(Zaragoza et al., 2002b).
Transient transfection of MC3T3-E1 cells
Transient transfections were conducted with Lipofectamine 2000 reagent as
described (Zaragoza et al., 2002b). MMP-13 promoter activity was measured by the
expression of the luciferase gene reporter. Experiments were carried out using the
Dual Luciferase Reporter system, co-transfecting BAEC with a pGL3 reporter
plasmid expressing Renilla under the control of a CMV promoter (pCMV-Renilla).
Gelatin zymography
MC3T3-E1 culture supernatants were collected over a time course of differentiation,
and gelatin zymography was conducted using pre-cast Biorad gelatin zymogram
gels, according to the manufacturer’s instructions.
MMP-13 activity assay
MMP-13 activity was assayed fluorimetrically using a fluorescent substrate from
Chemicon as previously described (Zaragoza et al., 2002a).
RNA isolation and RT-PCR
Total RNA was isolated by the guanidinium thiocyanate method as described
(Chomczynski and Sacchi, 1987). RNA was detected by real-time quantitative RT-
PCR, as previously described (Zaragoza et al., 2002b). The following primers were
selected: sense primer, 5-CCAAATTATGGAGGAGATGC-3; antisense primer, 5-
CGCCAGAAGAATCTGTCTTTAAA-3. As a reference gene, we used the
following primer set for glyceraldehyde-3 phosphate dehydrogenase (GAPDH):
sense primer, 5-AGTGGGTGATGCTGGTGCTG-3; antisense primer, 5-
CGCCTGCTTCACCACCTTCTT-3. The specificity of the amplification was
verified by resolution of the PCR products on ethidium bromide agarose gels.
Gene silencing
Cbfa-1 or GAPDH expression were silenced in MC3T3-E1 cells by transient
transfection of cells with pre-annealed siRNA oligonucleotides, corresponding to
specific regions of the murine Cbfa-1 and GAPDH genes (pre-validated siRNAs;
Ambion), as described (Lopez-Rivera et al., 2005).
Confocal microscopy
MMP-13 and Cbfa-1 from MC3T3-E1 were detected by confocal microscopy as
previously described (Lopez-Rivera et al., 2005).
In vitro phosphorylation assay
Recombinant Cbfa-1 was purified by nickel chromatograpy as described (Lopez-
Rivera et al., 2005). The efficacy of PKG to phosphorylate Cbfa-1 was tested by
incubating both proteins in the presence or absence of cGMP in phosphorylation
buffer (20 mM Tris HCl, pH 7.5; 10 mM MgCl2; 10 mM DTT; 20 mM ATP, 10
M NaF), containing 10 Ci [-32P]ATP, for 30 minutes at room temperature.
Proteins were then electrophoresed on 10% PAGE; the gels were washed with 10%
acetic acid, dried and exposed to autoradiography.
Statistical analysis
Unless otherwise specified, data are expressed as means ± s.d., and experiments
were performed at least three times in duplicate. Comparisons were made by non-
parametric statistics using the Wilcoxon Rank-Sum test whenever comparisons were
made with a common control. The level of statistical significance was defined as
P<0.05. Error bars represent ±s.d.
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